Assessment of neurocognitive function in association with WHO grades in gliomas

• Published in: Clinical neurology and neurosurgery Vol. 208; p. 106824
• Main Authors: Yamawaki, Rie, Nankaku, Manabu, Umaba, Chinatsu, Ueda, Masaya, Liang, Nan, Mineharu, Yohei, Yamao, Yukihiro, Ikeguchi, Ryosuke, Matsuda, Shuichi, Miyamoto, Susumu, Arakawa, Yoshiki
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.09.2021; Elsevier Limited
• Subjects: Adult; Aged; Brain cancer; Brain Neoplasms - pathology; Brain Neoplasms - psychology; Brain tumors; Central nervous system; Chemotherapy; Cognition; Cognition - physiology; Convulsions & seizures; Female; Glioma; Glioma - pathology; Glioma - psychology; Grade; Humans; Intelligence; Male; Memory; Middle Aged; Mutation; Neoplasm Grading; Nervous system; Neurocognitive function; Neurology; Neuropsychological Tests; Neuropsychology; Patients; Radiation therapy; Rehabilitation; Standard error of measurement; Variance analysis; WAIS-III; WMS-R; At/Co; WAIS-III; MQ; IDH1; PSI; Grade; POI; WMS-R; Neurocognitive function; KPS; NCF; DeR; WMI; FSIQ; Glioma; SEM; ViM; VCI; WHO; VeM
• ISSN: 0303-8467; 1872-6968
• DOI: 10.1016/j.clineuro.2021.106824

High-grade gliomas are fast-growing and may exhibit more severe neurocognitive function (NCF) decline compared with low-grade gliomas. A comprehensive understanding of the NCF in patients with glioma may be critical for developing effective glioma treatments and rehabilitation interventions. This study evaluated NCF more comprehensively in patients with glioma using the Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) and the Wechsler Memory Scale-Revised (WMS-R), and also determined the differences in NCF in relation with the WHO grades of gliomas. Thirty-five patients with newly diagnosed glioma were reviewed in the present study. The patients were divided into three groups, Grade II, III, and IV, based on the World Health Organization’s classification of tumors of the central nervous system. NCF was assessed using the WAIS-III and WMS-R. There were 14 (40.0%), 7 (20.0%), and 14 (40.0%) patients in the grade II, grade III, and grade IV groups, respectively. The results of the Kruskal-Wallis test showed significant differences in all the scores of the WAIS-III and WMS-R between grade II and grade IV. The scores of the WAIS-III and WMS-R in grade IV patients were borderline for NCF disorders, except in the attention/concentration domain. On the other hand, grade II and III groups had normal scores. Therefore, patients with a grade IV glioma presented NCF decline compared to grade II and III glioma. In contrast, the results of the WAIS-III and WMS-R indicated that the NCF of patients with grades II and III glioma was intact. •Neurocognitive function, in relation to the WHO grades of glioma, remains unclear.•Patients with grade IV glioma exhibited neurocognitive dysfunction before treatment.•Neurocognitive function of patients with grades II and III gliomas was intact.